VIDEX EC
DIDANOSINE
Approval overview VIDEX EC is listed in Drugs@FDA under application 021183 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient DIDANOSINE Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2018-12-17 00:00:00.
Structured Monograph
Clinical summary
Approval overview VIDEX EC is listed in Drugs@FDA under application 021183 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DIDANOSINE Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2018-12-17 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.